Table 2.
Preclinical Characteristics
| Preclinical Characteristics | Oritavancin | Vancomycin | P Value |
|---|---|---|---|
| N = 120 | N = 6695 | ||
| Preclinical Characteristics | |||
| Deyo Charlson Comorbidity Index (mean, SD)1 | 1.3 (1.8) | 1.5 (2.2) | .41 |
| Comorbid conditionsa (%) | |||
| Obesity | 25.0% | 19.0% | .10 |
| Diabetes without chronic complication | 22.5% | 26.2% | .36 |
| Depression | 17.5% | 15.4% | .53 |
| Diabetes with chronic complications | 15.0% | 15.5% | .88 |
| Chronic pulmonary disease | 14.2% | 10.7% | .23 |
| Renal failure | 13.3% | 11.8% | .61 |
| Cancer (nonleukemia) | 13.3% | 10.5% | .31 |
| Peripheral vascular disease | 8.3% | 7.2% | .63 |
| Connective tissue disease | 6.7% | 9.1% | .35 |
| Cerebrovascular disease | 5.0% | 4.2% | .68 |
| Prior antibioticsa | |||
| Beta-lactam agent | 50.0% | 49.9% | .98 |
| Fluoroquinolone | 26.7% | 20.3% | .09 |
| Lincosamide | 22.5% | 14.2% | .01 |
| Tetracycline | 22.5% | 14.1% | .01 |
| Lipoglycopeptide (daptomycin) | 11.7% | 0.2% | <.001 |
| Glycopeptide | 10.8% | 3.7% | .001 |
| Macrolide | 10.0% | 10.5% | .86 |
| Oxazolidinone | 4.2% | 1.0% | .10 |
| Other | 31.7% | 26.1% | .17 |
| Type of skin infection at diagnosisb | |||
| Cellulitis/abscess | 90.0% | 86.6% | .27 |
| Wound infection | 10.0% | 14.4% | .17 |
| Other skin infections | 17.5% | 14.0% | .27 |
| Site of infection at diagnosisb | |||
| Lower extremity | 58.3% | 42.0% | .001 |
| Upper extremity | 16.7% | 19.2% | .48 |
| Limb, unspecified | 16.7% | 10.1% | .02 |
| Abdomen/pelvis | 11.7% | 14.0% | .46 |
| Chest/trunk | 3.3% | 3.9% | 1 |
| Unspecified | 47.5% | 44.6% | .53 |
| Infection severity at diagnosisb | |||
| Life-threatening | 16 (13.3%) | 841 (12.6%) | .80 |
| Nonlife-threatening but with systemic symptoms | 17 (14.2%) | 1279 (19.1%) | .17 |
| Neither life threatening nor systemic symptoms | 91 (75.8%) | 4994 (74.6%) | .76 |
| Complicationsc (N, %) | |||
| Bacteremia | 6 (5.0%) | 197 (2.9%) | .17 |
| Endocarditis | 0 (0%) | 69 (1.0%) | .64 |
| Gangrene | 3 (2.5%) | 152 (2.3%) | .75 |
| Meningitis | 0 (0%) | 16 (0.2%) | 1.0000 |
| Necrotizing fasciitis | 2 (1.7%) | 42 (0.6%) | .18 |
| Osteomyelitis | 15 (12.5%) | 761 (11.4%) | .70 |
| Periprosthetic joint/device/graft infection | 5 (4.2%) | 408 (6.1%) | .38 |
| Septicemia/sepsis | 17 (14.2%) | 717 (10.7%) | .23 |
| Pre-Healthcare Resource Utilizationa | |||
| Prior inpatient hospitalization | 43.3% | 36.1% | .10 |
| Prior ER visit | 43.3% | 46.1% | .55 |
| Prior outpatient service | 98.3% | 95.4% | .13 |
| Patients with pharmacy claim | 95.0% | 92.5% | .31 |
| Total healthcare costs (mean, [SD]) | $31 280 (47 354) | $35 183 (74 109) | .57 |
| Median (IQR) | $16 308 (29 290) | $10 389 (36 902) |
Abbreviations: ER, emergency room; IQR, interquartile range; SD, standard deviation.
aMeasured during the baseline period (180 days prior to index day).
bMeasured during 7-day prior and 3-day on and after the index date.
cMeasured during 30-day prior and 3-day on and after the index date.